Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)
ApprovedCompleted 2 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Liver Cirrhosis
Conditions
Liver Cirrhosis, Liver Transplant Disorder
Trial Timeline
Feb 1, 2006 → Jun 1, 2008
NCT ID
NCT00296244About Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)
Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA) is a approved stage product being developed by Novartis for Liver Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00296244. Target conditions include Liver Cirrhosis, Liver Transplant Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Liver Cirrhosis were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00296244 | Approved | Completed |
Competing Products
20 competing products in Liver Cirrhosis